BioAlberta works with policymakers at all levels for a coordinated approach to setting public policy initiatives and ensuring the life sciences industry’s critical issues are well represented.

Through our Advocacy and Policy Committee, BioAlberta focuses on legislative and regulatory policy at the provincial level.

However, we also work with partner life science organizations across the country to support federal regulatory issues. Our Advocacy and Policy Committee is divided into subcommittees to answer the unique needs of each of the life science sectors.

Priority activities include:

  • Coverage of critical legislation and regulatory policy
  • Educating public officials about biotechnology
  • Encouraging greater support for life sciences entrepreneurship
  • Simplifying the regulatory environment, among other issues


The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

The Patented Medicine Prices Review Board has lost its way (again)

This commentary by W. Neil Palmer argues that the PMPRB has demonstrated little to no interest in patient health or health outcomes. It is time that changed.

November 1, 2022

BioAlberta's Letter to Jason Kenney

Re: Alberta’s Recovery Plan

July 22, 2020

Innovation Capital Working Group Submission

Subject: The struggle to access investment capital for Alberta companies

MARCH 4, 2020